Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” they are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy.

Biotechnology

HiberCell

Jonathan Lanfear

Hui Wang

Paulette Mattson

Michael Danielson

Kyle Michel

Julio Aguirre-Ghiso

Jeremy Drees

Haiguo Wu

Eric Lightcap

Cindy Jacobs Ph.D., M.D.

Beth Johnson

Crissy Dudgeon

José Iglesias

Jehan Rowlands

Nandita Bose

Ari Nowacek

The Scientific Advisory team at HiberCell provides critical expertise and strategic guidance on the therapeutic modulation of tumor dormancy. Comprised of leading experts, this team advises on research directions, evaluates scientific approaches, and ensures alignment with the latest advancements in oncology to help combat metastatic cancer.

Scientific Advisory

Leadership Team

Scientific and Clinical Research

Scientific Advisory

About

Team members

Other teams at HiberCell

Leadership Team

Scientific and Clinical Research